Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
9 10월 2026
Herbert Smith Freehills Kramer advises HEO on its US$25million Series B capital raise
HSF Kramer's venture & growth capital team has advised HEO on its US$25 million Series B capital raise. The round was led by Beaten Zone Venture …
9 10월 2026
Marissa J Holob and Kevin B Leblang named to 2027 Lawdragon 500 Leading Corporate Employment Lawyers list
Marissa J Holob and Kevin B Leblang have been named to the 2027 Lawdragon 500 Leading Corporate Employment Lawyers list.This guide recognizes and …
6 10월 2026
Herbert Smith Freehills Kramer files amicus brief in Second Circuit appeal on NYC congestion pricing
On September 23, 2026, HSF Kramer filed an amicus brief in the Second Circuit supporting the lower court’s decision in the appeal concerning New York …